Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
UROLOGY / CLINICAL RESEARCH
A new ASAP Scoring System and Risk Table to predict second prostate biopsy outcomes
1
Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
2
Department of Pathology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
3
Department of Pathology, Umraniye Education and Research Hospital, Istanbul, Turkey
Submission date: 2020-09-26
Final revision date: 2020-12-11
Acceptance date: 2020-12-18
Online publication date: 2021-10-15
Corresponding author
Ediz Caner
Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey, Tibbiye Sok. Selimiye Mah. Uskudar/Istanbul 34668 Phone: +90 533 580 50 80 Fax: +90 216 542 20 20
Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey, Tibbiye Sok. Selimiye Mah. Uskudar/Istanbul 34668 Phone: +90 533 580 50 80 Fax: +90 216 542 20 20
Arch Med Sci 2024;20(6):1894-1901
KEYWORDS
prostate-specific antigenprostate biopsyprostate canceratypical small acinar proliferationASAP Scoring System and Risk Table
TOPICS
ABSTRACT
Introduction:
This study aimed to discuss the necessity of a second prostate biopsy in patients with atypical small acinar proliferation (ASAP) and to develop a scoring system and risk table to be used as new criteria for a second biopsy.
Material and methods:
The study reviewed the data of 2,845 patients; who underwent transrectal ultrasonography-guided prostate biopsy in the period between January 2008 and May 2019. A total of 128 patients with ASAP were included in the study. The tPSA, fPSA, f/tPSA, and PSA-Density levels before the first and second biopsies and changes in the measured levels between the values obtained before the first and the second biopsies were recorded. “ASAP Scoring System and risk table” (ASS-RT) was evaluated before the second biopsy.
Results:
The mean age of 128 patients with ASAP was 62.9±7.8 years. The ASS-RT scores of prostate cancer patients were significantly higher compared to patients without prostate cancer (p: 0.001). In the ROC curve analysis of ASS-RT, the area under the curve was 0.804 and the standard error was 0.04. The area under the ROC curve was significantly higher than 0.5 (p:0.001). The cut-off point of ASS-RT scores in diagnosing cancer was ≥ 7 with 60.8% sensitivity and 80.5% specificity
Conclusions:
The cut-off value of 7 determined for the ASS-RT score in this study suggests that patients with ASS-RT scores of ≥7 should undergo a second prostate biopsy. We think that there may be no need for a second biopsy if the ASS-RT score is <7, especially for low-risk patients.
This study aimed to discuss the necessity of a second prostate biopsy in patients with atypical small acinar proliferation (ASAP) and to develop a scoring system and risk table to be used as new criteria for a second biopsy.
Material and methods:
The study reviewed the data of 2,845 patients; who underwent transrectal ultrasonography-guided prostate biopsy in the period between January 2008 and May 2019. A total of 128 patients with ASAP were included in the study. The tPSA, fPSA, f/tPSA, and PSA-Density levels before the first and second biopsies and changes in the measured levels between the values obtained before the first and the second biopsies were recorded. “ASAP Scoring System and risk table” (ASS-RT) was evaluated before the second biopsy.
Results:
The mean age of 128 patients with ASAP was 62.9±7.8 years. The ASS-RT scores of prostate cancer patients were significantly higher compared to patients without prostate cancer (p: 0.001). In the ROC curve analysis of ASS-RT, the area under the curve was 0.804 and the standard error was 0.04. The area under the ROC curve was significantly higher than 0.5 (p:0.001). The cut-off point of ASS-RT scores in diagnosing cancer was ≥ 7 with 60.8% sensitivity and 80.5% specificity
Conclusions:
The cut-off value of 7 determined for the ASS-RT score in this study suggests that patients with ASS-RT scores of ≥7 should undergo a second prostate biopsy. We think that there may be no need for a second biopsy if the ASS-RT score is <7, especially for low-risk patients.
REFERENCES (24)
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
2.
Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995; 154: 1791-4.
3.
Cheville JC, Reznicek MJ, Bostwick DG. The focus of “atypical glands, suspicious for malignancy” in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol 1997; 108: 633-40.
4.
Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F. Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as “atypical small acinar proliferation suspicious for but not diagnostic of malignancy”). Eur Urol 2006; 50: 666-74.
5.
Srirangam V, Rai BP, Abroaf A, et al. Atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia: should we be concerned? An observational cohort study with a minimum follow-up of 3 years. Curr Urol 2017; 10: 199-205.
6.
Leone L, Lacetera V, Montironi R, et al. Biopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy. Arch Ital Urol Androl 2014; 86: 332-5.
7.
Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2014; 12: 1211-9.
8.
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29.
9.
Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820-34.
10.
Ericson KJ, Wenger HC, Rosen AM, et al. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol 2017; 24: 8714-20.
11.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol 2013; 189: 867-70.
12.
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64: 876-92.
13.
Quaresima L, Lacetera V, Leone L, et al. The impact of repeated prostate biopsies on sexual function and urinary symptoms in patients with diagnosis of Atypical Small Acinar Proliferation (ASAP): can ecoDoppler reduce side effects? Arch Ital Urol Androl 2014; 86: 356-8.
14.
Fandella A. Analysis of costs of transrectal prostate biopsy. Urologia 2011; 78: 288-92.
15.
Ynalvez LA, Kosarek CD, Kerr PS, et al. Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm. Int Urol Nephrol 2018; 50: 1-6.
16.
Leone A, Rotker K, Butler C, et al. Atypical small acinar proliferation: repeat biopsy and detection of high grade prostate cancer. Prostate Cancer 2015; 2015: 810159.
17.
Leone A, Gershman B, Rotker K, et al. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer Prostatic Dis 2016; 19: 68-71.
18.
Mallen E, Gil P, Sancho C, et al. Atypical small acinar proliferation: review of a series of 64 patients. Scand J Urol Nephrol 2006; 40: 272-5.
19.
Sakura M, Kawakami S, Ishioka J, et al. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. Urology 2011; 77: 915-20.
20.
Moussa AS, Jones JS, Yu C, Fareed K, Kattan MW. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling. BJU Int 2010; 106: 1309-14.
21.
Yanke BV, Gonen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005; 173: 421-4.
22.
Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003; 170: 1184-8.
23.
Scattoni V, Roscigno M, Freschi M, et al. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl 2005; 77: 31-6.
24.
Chen R, Huang Y, Cai X, et al. Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0-10.0 ng/ml. PLoS One 2015; 10: e0130308.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
